Your Health, We Care
Capmatinib produced by Lucius Pharmaceuticals is available in the specification of 200 mg × 60 tablets.
The price of capmatinib may be affected by factors such as exchange rates, transportation costs and production costs.
Capmatinib is a targeted therapy for non-small cell lung cancer with MET exon 14···【more】
Release date：2026-03-13Recommended：47
Capmatinib (Tabrecta) is a highly selective MET receptor tyrosine kinase inhibit···【more】
Release date：2026-03-13Recommended：81
Capmatinib is an antineoplastic agent (cancer medication). It works by interferi···【more】
Release date：2026-01-09Recommended：92
Capmatinib is indicated for the treatment of metastatic (spread) non-small cell ···【more】
Release date：2026-01-09Recommended：107
Capmatinib is a targeted therapy for patients with non-small cell lung cancer wi···【more】
Release date：2024-08-06Recommended：339
Capmatinib is an oral drug manufactured by Novartis Pharmaceutical. It is a tyro···【more】
Release date：2024-08-06Recommended：285
Capmatinib inhibits the growth of cancer cells caused by specific genetic varian···【more】
Release date：2024-08-06Recommended：333
